Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 31, 2011 Brian Orelli	Better Buy? Seattle Genetics or ImmunoGen Battle of the heat-seeking cellular missiles.
The Motley Fool October 12, 2010 Brian Orelli	This Drugmaker Stands on a Platform Above the Rest ImmunoGen signs up another partner.
The Motley Fool October 12, 2010 Brian Orelli	Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks.
The Motley Fool September 14, 2010 Brian Orelli	This Bad News Could've Been Worse A Seattle Genetics drug fails, but there's more in the pipeline.
The Motley Fool April 8, 2011 Brian Orelli	ImmunoGen's Hot Start ImmunoGen scores some positive data, but were investors expecting less?
The Motley Fool September 27, 2010 Brian Orelli	Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin.
The Motley Fool July 10, 2008 Brian Lawler	Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks.
The Motley Fool December 29, 2011 Brian Orelli	What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key.
The Motley Fool February 9, 2007 Brian Lawler	Picking Up the Pace at Seattle Genetics The cash situation shows the shares of this drug development company could be appealing.
The Motley Fool October 1, 2008 Brian Orelli	3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear.
The Motley Fool January 10, 2007 Brian Lawler	Seattle Genetics' Big Deal The small biopharmaceutical firm signed a lucrative collaboration deal with biopharma powerhouse Genentech and shares were up 24% as a result.
The Motley Fool July 13, 2011 Brian Orelli	2 Questions for Seattle Genetics So far the FDA is fairly impressed with Seattle Genetics' lymphompa drug brentuximab vedotin.
Bio-IT World May 19, 2004 Barbara Depompa	Surging in Seattle Laid-back coastal-mountain lifestyle bolsters Northwestern biotech company.
The Motley Fool July 5, 2011 Luke Timmerman	Seattle Genetics, on the Verge of Going Commercial, Seeks to Keep Its Scientific Soul Expectations are sky-high.
The Motley Fool May 31, 2011 David Williamson	Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin...
The Motley Fool August 22, 2011 Brian Orelli	Speedy in Seattle Seattle Genetics gets an early approval of Adcentris.
The Motley Fool January 22, 2008 Brian Lawler	Seattle Genetics' Fortuitous Timing The drugmaker raises some much-needed cash with a $90 million stock offering.
The Motley Fool July 12, 2011 Luke Timmerman	Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug.
The Motley Fool August 20, 2011 Luke Timmerman	Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas.
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
The Motley Fool August 31, 2011 Brian Orelli	Antibodies: They're Not Just for Fighting Infection Anymore Therapeutic antibodies have continued to evolve since the first, OKT3, was approved back in 1986. Biotech investors had better pay attention, lest the technology passes them by.
The Motley Fool July 15, 2011 Brian Orelli	Seattle Genetics Will Work It Out This isn't the NFL labor negotiations.
The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
The Motley Fool September 3, 2010 Brian Orelli	Why You Just Got Hammered Celldex's decline is due to potential reasons Pfizer would send back a drug it's been working on with Celldex for over two years
The Motley Fool April 8, 2011 Brian Orelli	A Shutdown of Binary Events? A government shutdown will likely stop FDA approvals.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument.
The Motley Fool December 8, 2010 Brian Orelli	Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs.
The Motley Fool April 2, 2008 Brian Lawler	Seattle Genetics Bulks Up Its Pipeline Seattle Genetics biopharmaceutical clinical studies are firing on all cylinders.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool March 28, 2011 Brian Orelli	Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news.
The Motley Fool October 31, 2005 Charly Travers	A Myriad of Shares Management's predilection for excessive share dilution at Myriad Genetics is troubling for investors.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.
The Motley Fool January 12, 2005 Charly Travers	Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity.
The Motley Fool July 14, 2011 Luke Timmerman	Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel An FDA panel of cancer drug experts recommended in a 10-0 vote that the company's drug for Hodgkin's lymphoma should be cleared for sale in the U.S.
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.
The Motley Fool May 15, 2006 Brian Gorman	AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note.
The Motley Fool August 2, 2004 Charly Travers	What's a Drug Worth? The value of small biotech companies is in their investigational drug programs.
The Motley Fool July 28, 2009 Brian Orelli	I Can't Believe My Company Got Acquired Would you like some cheese with that whining? Investors buy into a biotech company hoping for a 10-bagger after a drug is approved. Instead, they end up getting capped at a double when the biotech gets acquired.
The Motley Fool October 20, 2006 Brian Lawler	Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth.
The Motley Fool December 4, 2008 Brian Orelli	Drug Deals Require Cash Pharmaceutical companies have been hoarding cash -- patiently waiting for good prices. And it looks like that time has arrived. Take a look at some players in the pharmaceutical field.
The Motley Fool December 11, 2006 Michael P. Cecil	Why Doesn't Buffett Buy Drug Companies? Investors, how do you estimate the amount of money that a drug company, or perhaps more simply one of its drugs, will produce over its lifetime?
The Motley Fool December 31, 2008 Brian Orelli	Health Care's Golden Children The whole industry wasn't down this year.
Bio-IT World March 17, 2004	Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006.
The Motley Fool June 29, 2009 Brian Orelli	Funding From an Unlikely Place Nonprofits still have money, and they seem willing to fork it over to for-profit drug companies.
The Motley Fool August 19, 2004 Charly Travers	Myriad's Making Hope Possible This small biotech provides screens that can help catch cancer. Even with solid growth of product revenue, losses could continue to increase as Myriad moves more drugs into clinical development while it transitions into a drug developer.
The Motley Fool February 26, 2011 Brian Orelli	FDA Applications and a Look Ahead It isn't pretty.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool April 20, 2004 Alyce Lomax	Pfizer's Fight First-quarter earnings give mixed messages on the drug maker's meds.